Skip navigation

 Login or Register | Member Centre

GlobeInvestorGOLD Canada's most comprehensive investment tool.

 
Change Symbol: Lookup Trade Now

Spectrum Pharmaceuticals Inc | Headlines

  • Vol:
  • Last Trade:
Search found 6 documents
1: Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference in New York City on Tuesday, February 9th
Business Wire, February 5, 2010 07:00 AM

2: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
Business Wire, February 2, 2010 06:00 AM

3: Spectrum Pharmaceuticals Announces Receipt of $16 Million from Asian Partners Related to Apaziquone Collaboration Agreements Announced in November 2009
Business Wire, January 29, 2010 07:00 AM

4: Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH) as It Continues to Prioritize Its Portfolio Strategy
Business Wire, January 27, 2010 07:03 AM

5: Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV® sNDA under Review for Advanced Metastatic Colorectal Cancer
Business Wire, January 25, 2010 07:00 AM

6: Spectrum Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Pivotal Trials for Apaziquone in Non-Muscle Invasive Bladder Cancer
Business Wire, January 12, 2010 07:00 AM

 

Search using one or more of the following options:

Symbol Lookup
 
 
  Search Tips
 
  * Can only be used when searching The Globe and Mail and newswires.

Back to top